Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2016 Jul 4;108(8):djw111.
doi: 10.1093/jnci/djw111. Print 2016 Aug.

RE: RNA Disruption Assay as a Biomarker of Pathological Complete Response in Neoadjuvant Trastuzumab-Treated Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer

Sinead Toomey  1 , Alex J Eustace  2 , Laura B Pritzker  1 , Ken P H Pritzker  1 , Joanna Fay  1 , Anthony O'Grady  1 , Robert Cummins  1 , Liam Grogan  1 , John Kennedy  1 , Darran O'Connor  1 , Leonie Young  1 , Elaine W Kay  1 , Norma O'Donovan  1 , William M Gallagher  1 , Roshni Kalachand  1 , John Crown  1 , Bryan T Hennessy  1
Affiliations
Comment

RE: RNA Disruption Assay as a Biomarker of Pathological Complete Response in Neoadjuvant Trastuzumab-Treated Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer

Sinead Toomey et al. J Natl Cancer Inst. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Biopsy cores taken 20 days after the initiation of neoadjuvant therapy by a radiologist were embedded in optical coherence tomography and the samples were cryo-sectioned. A single 3 µM section was taken for haematoxylin and eosin (H&E) staining and analysis and the adjacent ten 10 µm sections were cut and stored in a chilled cryovial. Following this, a second 3 µM section was then cut for H&E staining. Cut sections were stored at -80°C. We also performed RNA extractions on the cut sections using the QIAGEN RNAEasy kit, and quantified them on the Bioanalyser using the Agilent RNA 6000 Nano kit. RNA quantification files were then sent to RNA diagnostics for analysis using RNA disruption assay (RDA) as previously described. A and B) Pathological analysis of the H&E stained sections was conducted to assign a percentage tumor and a percentage stroma score to each sample. C) Correlation of RDA scores and pCR in 17 patient samples. P values were calculated using the Student's t test with a value of less than .05 being considered statistically significant. NR = no response; pCR = pathological complete response; PR = partial response.
See this image and copyright information in PMC

Comment in

  • Response.
    Trudeau M. Trudeau M. J Natl Cancer Inst. 2016 Jul 4;108(8):djw105. doi: 10.1093/jnci/djw105. Print 2016 Aug. J Natl Cancer Inst. 2016. PMID: 27377903 Free PMC article. No abstract available.

Comment on

References

    1. Pritzker K, Pritzker L, Generali D, et al. RNA Disruption and Drug Response in Breast Cancer Primary Systemic Therapy. J Natl Cancer Inst Monogr. 2015;2015(51):76–80. - PubMed
    1. Parissenti AM, Guo B, Pritzker LB, et al. Tumor RNA disruption predicts survival benefit from breast cancer chemotherapy. Breast Cancer Res Treat. 2015;153(1):135–144. - PubMed
    1. Foroni C, Milan M, Strina C, et al. Pure anti-tumor effect of zoledronic acid in naive bone-only metastatic and locally advanced breast cancer: proof from the "biological window therapy." Breast Cancer Res Treat. 2014;144(1):113–121. - PubMed
    1. Parissenti AM, Chapman JA, Kahn HJ, et al. Association of low tumor RNA integrity with response to chemotherapy in breast cancer patients. Breast Cancer Res Treat. 2010;119(2):347–356. - PubMed
    1. Crown J, Coate L, Keane M, et al. Randomized phase II study of pre-operative docetaxel, carboplatin with trastuzumab (TCH) and/or/lapatinib (L) in HER-2 positive (H+) breast cancer patients (BC pts). ICORG 10-05. Cancer Res. 2013;73(24 Suppl): abstract nr P4-12-25.